NCT01215838

Brief Summary

The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better at diagnosing liver lesions.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2010

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 28, 2010

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 7, 2010

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2012

Completed
Last Updated

October 14, 2013

Status Verified

October 1, 2013

Enrollment Period

1 year

First QC Date

September 28, 2010

Last Update Submit

October 11, 2013

Conditions

Hepatocellular Carcinoma

Keywords

HCChepatocellular carcinomaEovistMRMRImagnetic resonance

Outcome Measures

Primary Outcomes (1)

  • Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.

    One day: participants will have one MRI of the liver.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with known hepatocellular carcinoma undergoing MRI of the liver in the UWMC Radiology Clinic.

You may qualify if:

  • known hepatocellular carcinoma
  • undergoing MRI of the liver

You may not qualify if:

  • Contraindication to MRI with IV contrast

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. doi: 10.3322/canjclin.56.2.106.

    PMID: 16514137BACKGROUND

  • Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, Shimazaki Y. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4(1):1-9. doi: 10.2463/mrms.4.1.

    PMID: 16127248BACKGROUND

  • Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, Wolf KJ, Albrecht T. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009 Oct;193(4):1053-60. doi: 10.2214/AJR.08.1946.

    PMID: 19770329BACKGROUND

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

  • Orpheus Kolokythas, MD

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 28, 2010

First Posted

October 7, 2010

Study Start

August 1, 2010

Primary Completion

August 1, 2011

Study Completion

January 1, 2012

Last Updated

October 14, 2013

Record last verified: 2013-10